The patient with refractory ascites

Best Practice and Research in Clinical Gastroenterology

Volumn 21, Issue 3, 2007, Pages 551-560

  Gerbes, Alexander L ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

aquaretics; hepatorenal syndrome; paracentesis; spontaneous bacterial peritonitis; terlipressin; transjugular intrahepatic portosystemic shunt (TIPS)

Indexed keywords

ALBUMIN; CEFOTAXIME; DIURETIC AGENT; PENTOXIFYLLINE; PLACEBO; RECEPTOR BLOCKING AGENT; TERLIPRESSIN; UNCLASSIFIED DRUG; VASOPRESSIN DERIVATIVE; VASOPRESSIN V2 RECEPTOR ANTAGONIST;

ARTICLE; ASCITES; BACTERIAL PERITONITIS; CHRONIC LIVER DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; HUMAN; LIVER TRANSPLANTATION; LOW DRUG DOSE; MONOTHERAPY; PORTOSYSTEMIC ANASTOMOSIS; PROGNOSIS;

ASCITES; BACTERIAL INFECTIONS; FEMALE; HUMANS; LIVER DISEASES; MIDDLE AGED; PARACENTESIS; PERITONITIS;

EID: 34249670287     PISSN: 15216918     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bpg.2006.12.001     Document Type: Article

References (33)

1. Jungst D., Xie Y., and Gerbes A.L. Pathophysiology of elevated ascites fluid cholesterol in malignant ascites. Increased ascites to serum relation of proteins and lipoproteins in patients with peritoneal carcinomatosis as compared to patients with cirrhosis of the liver. J Hepatol 14 (1992) 244-248
2. Gerbes A.L., Jungst D., Xie Y.N., et al. Ascitic fluid analysis for the differentiation of malignancy-related and non-malignant ascites. Cancer 68 8 (Oct 15 1991) 1808-1814
3. Arroyo V., Gines P., Gerbes A.L., et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 23 (1996) 164-176
4. Runyon B.A. Practice Guidelines Committee American Association for the Study of Liver Diseases (AASLD). Management of adult patients with ascites due to cirrhosis. Hepatology 40 (2004) 841-856
5. Castellote J., Lopez C., Gornals J., et al. Rapid diagnosis of spontaneous bacterial peritonitis by use of reagent strips. Hepatology 37 (2003) 893-896
6. Sort P., Navasa M., Arroyo V., et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 341 (1999) 403-409
7. Gerbes A.L., Gülberg V., Waggershauser T., et al. Renal effects of transjugular intrahepatic portosystemic shunt in cirrhosis: comparison of patients with ascites, with refractory ascites, or without ascites. Hepatology 28 (1998) 683-688
8. Rossle M., Ochs A., Gülberg V., et al. A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites. N Engl J Med 342 (2000) 1701-1707
9. Gines P., Uriz J., Calahorra B., et al. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology 123 (2002) 1839-1847
10. Sanyal A.J., Genning C., Reddy K.R., et al. The North American study for the treatment of refractory ascites. Gastroenterology 124 (2003) 634-641
11. Salerno F., Merli M., Riggio O., et al. Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites. Hepatology 40 (2004) 629-635
12. Gerbes A.L., and Gülberg V. Benefit of TIPS for patients with refractory or recidivant ascites: serum bilirubin may make the difference. Hepatology 41 (2005) 217
13. Gülberg V., Liss I., Bilzer M., et al. Improved quality of life in patients with refractory or recidivant ascites after insertion of transjugular intrahepatic portosystemic shunts. Digestion 66 (2002) 127-130
14. Gerbes A.L. Therapy of ascites in liver disease. Z Gastroenterol 35 (1997) 295-300
15. Grabau C.M., Crago S.F., Hoff L.K., et al. Performance standards for therapeutic abdominal paracentesis. Hepatology 40 (2004) 484-488
16. Lin C.H., Chen S.C., and Koh P.C. Pre-procedure coagulation tests are unnecessary before abdominal paracentesis in emergency departments. Hepatology 41 (2005) 402-403
17. Moore K.P., Wong F., Gines P., et al. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology 38 (2003) 258-266
18. Sola-Vera J., Minana J., Ricart E., et al. Randomized trial comparing albumin and saline in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients with ascites. Hepatology 37 (2003) 1147-1153
19. Gerbes A.L., Gülberg V., Gines P., et al. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. Gastroenterology 124 (2003) 933-939
20. Wong F., Blei A.T., Blendis L.M., and Thuluvath P.J. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology 37 (2003) 182-191
21. Gines P., Guevara M., Arroyo V., and Rodes J. Hepatorenal syndrome. Lancet 362 (2003) 1819-1827
22. Akriviadis E., Botla R., Briggs W., et al. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 119 (2000) 1637-1648
23. Gonwa T.A., Klintmalm G.B., Levy M., et al. Impact of pretransplant renal function on survival after liver transplantation. Transplantation 15 59 (1995) 361-365
24. Schrier R.W., Arroyo V., Bernardi M., et al. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 8 (1988) 1151-1157
25. Ruiz-del-Arbol L., Monescillo A., Arocena C., et al. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology 42 (2005) 439-447
26. Brensing K.A., Textor J., Perz J., et al. Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut 47 (2000) 288-295
27. Gülberg V., Bilzer M., and Gerbes A.L. Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine. Hepatology 30 (1999) 870-875
28. Uriz J., Ginès P., Cárdenas A., et al. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol 33 (2000) 43-48
29. Wong F., and Blendis L. New challenge of hepatorenal syndrome: prevention and treatment. Hepatology 34 (2001) 1242-1251
30. Moreau R., Durand F., Poynard T., et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology 122 (2002) 923-930
31. Solanki P., Chawla A., Garg R., et al. Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial. J Gastroenterol Hepatol 18 (2003) 152-156
32. Mitzner S.R., Stange J., Klammt S., et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis. Liver Transplant 6 (2000) 277-286
33. Sen S., Davies N.A., Mookerjee R.P., et al. Pathophysiological effects of albumin dialysis in acute-on-chronic liver failure: a randomized controlled study. Liver Transplant 10 (2004) 1109-1119